1. [Disseminated intravascular coagulation syndrome and thromboembolic complications of non-small-cell lung cancer. A case report].
- Author
-
Sakhri L, Jeung MY, Forher C, Pauli G, Quoix E, and Mennecier B
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma diagnostic imaging, Adenocarcinoma mortality, Blood Coagulation Tests, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung mortality, Disseminated Intravascular Coagulation diagnosis, Echocardiography, Female, Humans, Intracranial Thrombosis etiology, Karnofsky Performance Status, Lung Neoplasms diagnosis, Lung Neoplasms diagnostic imaging, Lung Neoplasms mortality, Middle Aged, Pulmonary Embolism etiology, Radiography, Abdominal, Radiography, Thoracic, Shock, Cardiogenic etiology, Stroke diagnostic imaging, Stroke etiology, Tomography, X-Ray Computed, Adenocarcinoma complications, Carcinoma, Non-Small-Cell Lung complications, Disseminated Intravascular Coagulation complications, Lung Neoplasms complications, Thromboembolism etiology
- Abstract
Hemostatic disorders can be found in approximately 90% of cancer patients, but clinical expression in only 15%. Hemorrhagic complications are more frequent in acute leukaemia; solid tumors are often associated with deep venous thromboses (DVP). Disseminated intravascular coagulation syndrome (DICS) can be latent or acute, and has various clinical presentations, occurring in the course of many serious conditions including cancer. Patients have higher morbidity and mortality. Irrespective of the etiology, DICS can be revealed by a wide variety of clinical manifestations, from mild biological hemostasis disorders, to intravascular or extravascular microthromboses or lethal hemorrhagic events. We report the case of a 45-year-old female with non-small-cell lung cancer with metastases at diagnosis. The patient developed and finally died of numberous thromboembolic events subsequent to DICS. This case illustrates some rather rare complications of DICS and offers the opportunity to discuss the main therapeutic goal in this situation, i.e. to modulate the disproportionate production of thrombin, inducing thromboses and/or hemorrhages by consumption of the cellular and plasmatic coagulation factors. This means a symptomatic and mostly etiologic treatment, especially chemotherapy which can in itself provoke thromboembolic events.
- Published
- 2007
- Full Text
- View/download PDF